All In Biotech

Drug Trial Radar · NCT01926496

Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%

A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial

Last checked: Nov 20, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 485 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

485

Actual

Start

Sep 11, 2013

Primary completion

Jul 11, 2019

Study completion Jul 11, 2019

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Aug 21, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the risk of developing squamous skin cancer (SCC) or other types of cancer after treatment of AKs with ingenol mebutate gel or imiquimod cream. Subjects will be randomised to treatment with ingenol mebutate or imiquimod and will receive a second treatment cycle with the same treatment if the first treatment does not clear all AKs. Subjects will be followed over a period of three year (36 months) after first treatment

Conditions

  • Actinic Keratosis (AK)

Interventions

  • Ingenol Mebutate Gel, 0.015%Drug

    Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.

  • Imiquimod Cream, 5%Drug

    Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of SCCTime frame: 3 years

Locations

46 sites in 3 countries. Site status is shown where the registry gives one.

  • CHU Angers - Service de Dermatologie

    Angers, France

  • CHU Besançon - Hôpital Jean Minjoz

    Besançon, France

  • HOPITAL AVICENNE - Service de Dermatologie

    Bobigny, France

  • CHRU de Brest - Hôpital Morvan - Service de Dermatologie

    Brest, France

  • CHU Albert Michallon - Service de Dermatologie, Pôle Pluridisciplinaire de Médecine

    Grenoble, France

  • Hôpital Claude Huriez - CHRU de Lille - Clinique de Dermatologie

    Lille, France

  • Hôpital de la Timone - Service de Dermatologie Vénérologie

    Marseille, France

  • CHU de Nantes - Hôtel Dieu - Unité Fonctionnelle de Dermatologie Cancérologie

    Nantes, France

  • HOPITAL DE L ARCHET II - Service de Dermatologie-Vénérologie

    Nice, France

  • Hôpital Caremeau

    Nîmes, France

  • HOPITAL COCHIN TARNIER - Service de Dermatologie

    Paris, France

  • Hôpital Saint Louis - Service de Dermatologie

    Paris, France

  • CHU BORDEAUX - Hôpital Haut-Lévêque

    Pessac, France

  • CHU Poitiers - Service de Dermatologie

    Poitiers, France

  • C.H.U. de Saint-Etienne - Hôpital Nord

    Saint-Etienne, France

  • Hôpital d'instruction des Armées Bégin - Clinique Dermatologique

    Saint-Mandé, France

  • Hautarztpraxis Simon

    Berlin, Germany

  • Hauttumorzentrum Bochum Universitätsklinikum der Ruhr-Universität-Bochum

    Bochum, Germany

  • Praxis Streit Bucholz

    Buchholz, Germany

  • Dermatologisches Zentrum, Am Krankenhaus 1

    Buxtehude, Germany

  • Klinikum Dortmund - Hautklinik

    Dortmund, Germany

  • Mensingderma

    Hamburg, Germany

  • Universitätsklinikum Leipzig Klinik für Dermatologie, Venerologie und Allergologie

    Leipzig, Germany

  • Hautpraxis Dr. Ina Schulze

    Markkleeberg, Germany

  • Hauttumorzentrum Münster

    Münster, Germany

  • Klinik für Dermatologie und Allergologie, Klinikum Vest, Behandlungszentrum, Knappschaftskrankenhaus Recklinghausen,

    Recklinghausen, Germany

  • Universitätklinikum Regensburg

    Regensburg, Germany

  • Praxis Dr. Hoffmann

    Witten, Germany

  • Praxis Derma Hübinger

    Wuppertal, Germany

  • Universitätsklinikum Würzburg

    Würzburg, Germany

  • Hull Royal Infirmary

    Hull, United Kingdom

  • Ninewells Hospital

    Dundee, Angus, United Kingdom

  • Cumberland Infirmary

    Carlisle, Cumbria, United Kingdom

  • Heavitree Hospital

    Exeter, Devon, United Kingdom

  • Brighton General Hospital

    Brighton, East Sussex, United Kingdom

  • Manchester Royal Infirmary

    Manchester, Greater Manchester, United Kingdom

  • Monklands Hospital

    Airdrie, Lanarkshire, United Kingdom

  • Scunthorpe General Hospital

    Scunthorpe, Lincolnshire, United Kingdom

  • Royal Gwent Hospital

    Newport, Monmouthshire, United Kingdom

  • Harrogate District Hospital

    Harrogate, North Yorkshire, United Kingdom

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.